Brainstorm Cell Therapeutics (NASDAQ:BCLI) COO Ralph Dr. Kern purchased 5,000 shares of Brainstorm Cell Therapeutics stock in a transaction that occurred on Thursday, March 15th. The shares were acquired at an average price of $3.60 per share, with a total value of $18,000.00. The purchase was disclosed in a legal filing with the SEC, which is available through this link.

Shares of Brainstorm Cell Therapeutics (NASDAQ BCLI) traded up $0.09 during trading hours on Friday, hitting $3.33. The stock had a trading volume of 20,780 shares, compared to its average volume of 60,491. Brainstorm Cell Therapeutics has a 12 month low of $2.88 and a 12 month high of $5.18. The company has a market capitalization of $61.42, a PE ratio of -12.35 and a beta of 1.95.

How to Become a New Pot Stock Millionaire

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last issued its quarterly earnings data on Thursday, March 8th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.11. research analysts expect that Brainstorm Cell Therapeutics will post -0.66 earnings per share for the current year.

Several large investors have recently modified their holdings of the company. Vanguard Group Inc. boosted its holdings in shares of Brainstorm Cell Therapeutics by 2.8% during the second quarter. Vanguard Group Inc. now owns 657,101 shares of the biotechnology company’s stock worth $2,733,000 after acquiring an additional 17,657 shares during the period. Clearline Capital LP bought a new stake in shares of Brainstorm Cell Therapeutics during the fourth quarter worth approximately $208,000. Deutsche Bank AG boosted its holdings in shares of Brainstorm Cell Therapeutics by 330.0% during the fourth quarter. Deutsche Bank AG now owns 98,590 shares of the biotechnology company’s stock worth $386,000 after acquiring an additional 75,664 shares during the period. Finally, Renaissance Technologies LLC boosted its holdings in shares of Brainstorm Cell Therapeutics by 396.9% during the fourth quarter. Renaissance Technologies LLC now owns 114,550 shares of the biotechnology company’s stock worth $449,000 after acquiring an additional 91,495 shares during the period. Institutional investors own 9.54% of the company’s stock.

BCLI has been the subject of a number of research analyst reports. Maxim Group set a $9.00 price objective on Brainstorm Cell Therapeutics and gave the stock a “buy” rating in a report on Wednesday, December 27th. ValuEngine cut Brainstorm Cell Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, December 21st.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece of content on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The legal version of this piece of content can be read at https://www.watchlistnews.com/brainstorm-cell-therapeutics-bcli-coo-purchases-18000-00-in-stock/1961204.html.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders that include amyotrophic lateral sclerosis, multiple sclerosis, Parkinson's disease, and others. The company holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd.

Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.